Bemarituzumab Elicits Positive Overall Survival in FGFR2b-Positive First-Line Gastric Cancer

Bemarituzumab Elicits Positive Overall Survival in FGFR2b-Positive First-Line Gastric Cancer

The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved its primary goal.The post Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint appeared first on Clinical Trials Arena.

Bemarituzumab Plus Chemo Improves OS in FGFR2b+ Gastric Cancer

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options.